DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOLTERODINE TARTRATE

« Back to Dashboard

Clinical Trials for Tolterodine Tartrate

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00143377	Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB	Completed	Pfizer	Phase 4	The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.
NCT00293839	Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder	Completed	Alza Corporation, DE, USA	Phase 3	The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.
NCT00454740	Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
NCT00768521	A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)	Completed	Merck Sharp & Dohme Corp.	Phase 1	This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.

Clinical Trial Conditions for Tolterodine Tartrate

Condition Name

Condition Name for Tolterodine Tartrate
Intervention	Trials
Overactive Bladder	4
Urinary Incontinence	2
Lower Urinary Tract Symptoms	1
Atrial Fibrillation	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tolterodine Tartrate
Intervention	Trials
Urinary Bladder, Overactive	7
Urinary Incontinence	3
Enuresis	2
Lower Urinary Tract Symptoms	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tolterodine Tartrate

Trials by Country

Trials by Country for Tolterodine Tartrate
Location	Trials
United States	35
China	2
Brazil	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tolterodine Tartrate
Location	Trials
Georgia	2
California	2
Texas	2
Missouri	1
Nevada	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tolterodine Tartrate

Clinical Trial Phase

Clinical Trial Phase for Tolterodine Tartrate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2/Phase 3	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tolterodine Tartrate
Clinical Trial Phase	Trials
Completed	8
Not yet recruiting	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tolterodine Tartrate

Sponsor Name

Sponsor Name for Tolterodine Tartrate
Sponsor	Trials
Merck Sharp & Dohme Corp.	1
Federal University of São Paulo	1
Astellas Pharma Inc	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tolterodine Tartrate
Sponsor	Trials
Industry	7
Other	5

Export unavailable in trial.
Subscribe for complete access.